ANDREW HAGGERTY: Open Payments
NPI 1902512924 · PAPILLION, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,620 in 103 payments from 21 companies in 2025. Trend: 2023 $1,064 · 2024 $1,685 · 2025 $1,620
Food & beverage: $1,620
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $486 |
| Novo Nordisk Inc | 15 | $175 |
| PFIZER INC. | 13 | $174 |
| Lilly USA, LLC | 5 | $103 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $93 |
| Otsuka America Pharmaceutical, Inc. | 5 | $89 |
| AstraZeneca Pharmaceuticals LP | 5 | $79 |
| Astellas Pharma US Inc | 2 | $51 |
| Axsome Therapeutics, Inc. | 3 | $49 |
| Boston Scientific Corporation | 2 | $48 |
Products named: VRAYLAR, UBRELVY, REXULTI, Wegovy, QULIPTA, CAPLYTA, MOUNJARO, PREVNAR 20.
Industry payments across NE — which companies pay providers there.
